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SYNOPSIS
Neonatal bacterial meningitis is an uncommon but devastating infection. Although the incidence 
and mortality have declined over the last several decades, morbidity among survivors remains 
high. The types and distribution of causative pathogens are related to birth gestational age, 
postnatal age, and geographic region. Confirming the diagnosis of meningitis can be difficult. 
Clinical signs are often subtle, and the lumbar puncture is frequently deferred in clinically unstable 
infants. When obtained, confirmatory testing with cerebrospinal fluid (CSF) culture is often 
compromised by antepartum or postnatal antibiotic exposure. While blood cultures and CSF 
parameters may be helpful in cases where the diagnosis is uncertain, bacterial meningitis occurs in 
infants without bacteremia and with normal CSF parameters. Newer tests such as the polymerase 
chain reaction are promising but require further study. Prompt treatment with appropriate 
antibiotics is essential to optimize outcomes. Successful efforts to prevent meningitis in infants 
have included the use of intrapartum antibiotic prophylaxis against Group B Streptococcus (GBS). 
Clinical trials investigating the use of a GBS vaccine for the prevention of neonatal GBS disease 
are ongoing.
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INTRODUCTION
Bacterial meningitis is a devastating infection associated with high mortality and morbidity 
in the neonatal population. Prompt diagnosis and treatment are essential to achieving good 
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outcomes in affected infants. While overall incidence and mortality have declined over the 
last several decades, morbidity associated with neonatal meningitis remains virtually 
unchanged.1, 2 Prevention strategies, adjunctive therapies, and improved diagnostic 
strategies have been the focus of recent research seeking to improve the outcomes.3
DESCRIPTION OF THE DISEASE
Meningitis is the acute inflammation of the meninges, subarachnoid space, and brain 
vasculature resulting from infection.4 Neonatal meningitis is categorized as early and late 
onset, which is defined by the presence of signs of infection and organism isolation from 
cerebrospinal fluid (CSF) cultures at ≤72 hours and >72 hours of life, respectively.3, 5–7
EPIDEMIOLOGY
The incidence of neonatal meningitis varies by geographic location (Figure 1).8–10 
Compared with older age groups, the incidence of meningitis is highest during the neonatal 
period.9, 16
Developed Countries
The incidence of culture-proven neonatal meningitis is estimated at 0.3 per 1000 live births 
in developed countries. 2, 10, 16 This is likely an underestimation of the true incidence, 
however. For infants in the intensive care nursery who are evaluated for sepsis, 30–50% do 
not have a lumbar puncture (LP) performed.6, 17 When an LP is performed, more than 75% 
of the time it occurs after the initiation of antibiotics, possibly biasing CSF culture 
results.6, 17, 18.
In developed countries, mortality from neonatal meningitis ranges from 10–15%.2, 8 In a 
prospective study including 444 cases of confirmed meningitis from 2001–2007, mortality 
in premature infants compared with term infants was >2-fold higher (26% vs. 10%, p < 
0.01).8 Up to 50% of infants with a history of meningitis will be neurologically impaired, 
with 25% having severe disability.2, 8, 19 With advances in medical practices, the incidence 
and mortality associated with meningitis have declined over the past 40 years; however, 
morbidity remains unchanged.19
Developing Countries
In developing countries, the reported incidence of neonatal meningitis is much higher at 0.8–
6.1 per 1000 live births, with a mortality of 40–58%.9, 11 True values may actually be higher 
because of underreporting in regions with limited resources, diagnostic testing, and access to 
health care.9
ETIOLOGY
The types and distribution of organisms commonly observed in neonatal meningitis depend 
on postnatal age, location, and gestational age. The distribution of organisms seen in 
neonatal meningitis is similar to neonatal sepsis (Table 1.).1, 6, 16
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Despite the institution of maternal intrapartum prophylaxis, Group B Streptococcus (GBS) 
has remained the most common cause of neonatal sepsis and meningitis since the early 
1980s, responsible for >40% of all early-onset infections.2, 6, 20 Escherichia coli (E. coli) is 
the second most common pathogen and is isolated in 30% of all early-onset infections.6 
Since the 1990s, E. coli has emerged as the most common cause of early-onset sepsis and 
meningitis among very low birth weight (VLBW, <1500 g birth weight) infants.21–24
Late-Onset Meningitis
Late-onset meningitis is predominantly seen in premature infants, and the incidence is 
directly related to decreasing birth gestational age and weight.25 Surveillance of 6956 
VLBW infants from 1998–2000 found coagulase-negative staphylococci (48%) and 
Staphylococcus aureus (8%) to be the first and second most common pathogens, 
respectively.7 E. coli (5%) and Klebsiella (4%) spp. were the most common gram-negative 
causes of late-onset infections.5, 7 Although GBS (2%) was less common in this cohort, 
other studies found that infants were more likely to have confirmed meningitis with late-
onset GBS sepsis compared with early-onset GBS sepsis (Table 2).7, 26, 27
PATHOGENESIS
While several mechanisms in the development of neonatal meningitis have been described, 
primary bloodstream infection with secondary hematogenous distribution to the central 
nervous system (CNS) is the most common (Box 1).16 For this reason, the epidemiology and 
microbiology of neonatal meningitis is similar to neonatal sepsis.1
Early-Onset Infection
Organisms present in the maternal genitourinary tract ascend from the vagina and can infect 
the amniotic fluid through disruptions in the amniotic membranes, which the infant then 
aspirates.28 Organisms can also colonize exposed neonatal skin and mucosa during passage 
through the birth canal and invade through barrier disruptions.1 Organisms such as Listeria 
monocytogenes can also be transmitted transplacentally.16 In rare cases, hematogenous 
transmission of GBS from maternal bacteremia has been reported as a cause of early-onset 
GBS infections in infants.29
Late-Onset Infection
Organisms can be acquired from the colonized mother, as seen with GBS.30, 31 Poor hand 
hygiene among caregivers and hospital staff can result in the transfer of organisms between 
infected and uninfected infants.32 Foreign, invasive devices such as ventricular reservoirs, 
ventricular shunts, endotracheal tubes, venous or arterial catheters, urinary catheters, and 
feeding tubes can also introduce pathogens to the infant.16. Exposure to prolonged courses 
of empirical antibiotics for suspected infections can also result in increased risk for late-
onset infections.33 Among 365 VLBW infants ≤32 weeks gestational age, infants exposed to 
empirical antibiotics ≥5 days had increased odds of developing late-onset sepsis (OR, 2.45 
[95% CI, 1.28–4.67]).34
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Infection of the CNS
After attaching to the endothelium of the cerebral microvasculature and choroid plexus, 
bacteria can enter the CSF by several mechanisms (Box 2).1, 4, 35 Inflammatory mediators 
are then released into the CSF in response to the presence of bacterial products, resulting in 
meningitis and increased permeability of the blood-brain barrier.1, 31
RISK FACTORS
Risk factors for the development of neonatal meningitis are similar to neonatal sepsis (Box 
3).5, 10, 36 Immaturity of the neonatal immune system, impaired phagocytic ability of 
neutrophils and monocytes, and diminishing maternal antibodies all contribute to increased 
risk of infections in both term and preterm infants.4, 24 Because most maternal 
immunoglobulins do not cross the placenta before 32 weeks gestation, infants born 
extremely preterm are at significantly higher risk for infections.10 Early initiation of 
breastfeeding may be protective against infections, however, due to transfer of 
immunoglobulin A.37
CLINICAL PRESENTATION
The clinical signs of neonatal meningitis can be subtle and nonspecific (Box 4).16, 19, 38 
Meningitic signs such as convulsions, irritability, bulging fontanel, and nuchal rigidity are 
often late findings that are associated with poor outcomes.2, 10, 38
Exposure to intrapartum antibiotic prophylaxis (IAP) against GBS has led to concerns that 
the signs of neonatal infections could be delayed or masked. Several studies have 
determined no significant difference in the clinical presentation of early-onset GBS disease 
between infected infants with and without prior exposure to IAP.20 Signs of early-onset 
sepsis manifested in 90% of infected infants within the first 24 hours of life.20
DIAGNOSIS
To confirm the diagnosis of neonatal meningitis, an LP is needed to collect CSF. Positive 
growth on the CSF culture provides identification of the offending organism and enables 
refinement of therapy.2, 39 The LP is frequently deferred during the septic workup due to 
concerns of exacerbating clinical deterioration in the sick infant.39–41
Performing or Deferring the LP
Because the LP is an invasive procedure with risks, it is difficult to determine which infant 
should receive one as part of the septic workup.40, 41 Among infants with positive blood 
cultures, up to 30% will have a concurrent positive CSF culture.42 However, in infants with 
confirmed meningitis, 15–38% will have a negative blood culture.27, 43–45 In rare cases, the 
blood and CSF cultures can be discordant.44 Approaches in which only infants with 
confirmed bacteremia are evaluated for meningitis will result in missed diagnoses of 
meningitis.
The incidence of meningitis among asymptomatic infants with risk factors is very low 
(<1%).46, 47 When clinical signs can be attributed to noninfectious causes, such as 
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respiratory distress syndrome or transient tachypnea of the newborn, clinical judgment is 
required in deciding when to perform an LP.43 Among 238 infants admitted for respiratory 
distress without other symptoms, 17/238 (7%) infants had a positive blood culture, and none 
were found to have meningitis.48
The current recommendation is to perform an LP on all clinically stable infants suspected to 
have early- or late-onset sepsis and who are exhibiting signs of infection.20, 39, 43 Whenever 
possible, the LP should be performed prior to the administration of antibiotics.
Interpreting CSF Parameters
Infants are often exposed to intrapartum or empiric antibiotics prior to receiving an LP, 
which can result in falsely negative CSF cultures in those with meningitis.18 In these cases, 
CSF parameters are used to help determine the likelihood of meningitis.
CSF indexes vary according to age, with normal values in infants poorly defined.16, 44, 45 
Common practice states that a CSF leukocyte count ≥20/mm3 is suggestive of bacterial 
meningitis in the infant.16 A study involving 1064 infants demonstrated that infants <28 
days old without bacterial meningitis had a median CSF leukocyte count of 3/mm3 and 95th 
percentile value of 19/mm3.49 However, in a study evaluating 9111 infants ≥34 weeks 
gestational age, the use of 20/mm3 as a cutoff resulted in a missed diagnosis in 13% of 
infants with confirmed meningitis.44 Several infants with confirmed meningitis had normal 
CSF parameters without bacteremia. CSF protein and glucose were considered poor 
predictors of meningitis due to considerable overlap of values between infants with and 
without confirmed meningitis. A study of 4632 infants <34 weeks gestational age reached 
similar conclusions in the preterm population.45 There is great difficulty in predicting the 
diagnosis of meningitis solely based on CSF parameters, suggesting that CSF culture 
continues to be the gold standard for diagnosis.
Ancillary Tests
The polymerase chain reaction (PCR) has been explored as a diagnostic tool for meningitis. 
In addition to improved sensitivity and specificity, PCR also allows quicker detection of 
pathogens compared with traditional cultures.50 A real-time PCR assay designed to detect 
multiple pathogens including Streptococcus pneumonia, E. coli, GBS, S. aureus, and L. 
monocytogenes had an overall higher detection rate of any CSF pathogen compared with 
traditional cultures (72% vs. 48%).51 Among patients exposed to antibiotics before 
collection of CSF, PCR had a higher detection rate compared with culturing (58% vs. 
29%).51 Further testing is needed before PCR can be used routinely in the diagnosis of 
bacterial meningitis.52
Other tests used to aid in clinical decision-making include the complete blood count with 
differential and C-reactive protein. Studies examining the usefulness of these tests in the 
diagnosis of neonatal bacterial meningitis are limited (Table 3).
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The need for a repeat LP during treatment in an infant with confirmed meningitis has been 
debated. Some experts recommend routinely repeating an LP in all patients at 48 hours, 
whereas others suggest repeating an LP only if clinical conditions are not improved by 24–
72 hours after beginning therapy.56–59
In a retrospective study of 14,018 infants, 221 infants were identified as having culture-
positive meningitis, with 118 infants (53%) receiving ≥2 LPs during the treatment course.56 
Among infants with available mortality data receiving ≥2 LPs, 6/23 (26%) infants with 
repeat positive cultures died compared with 6/81 (7%) infants with repeat negative cultures 
(p=0.02). No significant difference in mortality was seen among the 81 (7%) infants with a 
repeat negative culture compared with the 90 (12%) infants with meningitis with no repeat 
LP (p=0.32). A survey of 109 pediatricians and neonatologists across northwest England 
found that 89 (82%) practitioners did not routinely repeat the LP in infants with bacterial 
meningitis unless clinically indicated.57
TREATMENT
Antimicrobial Therapy
Prompt initiation of antibiotics is critical. Delays in treatment are associated with increased 
mortality and morbidity.60 Empiric antimicrobials used in suspected meningitis require 
adequate CSF penetration and sensitivity against the most probable pathogens.10, 60 Upon 
identification of the pathogen and its susceptibilities, antimicrobial coverage should be 
adjusted accordingly (Table 4).
Duration of Antimicrobial Therapy
For uncomplicated meningitis, the minimum recommended treatment durations are the 
following:10, 61, 64
• 14 days for GBS, L. monocytogenes, and S. pneumonia
• 21 days for Pseudomonas and gram-negative enteric bacteria such as E. coli
Longer treatment courses are recommended for infants with meningitis with delayed clinical 
improvement after beginning therapy or with complications such as brain abscesses, 
ventriculitis, or brain infarctions.62
Adjunctive Therapy
In an effort to improve outcomes in infants with meningitis, several adjunctive therapies 
have been explored, including the use of intraventricular antibiotics, dexamethasone, 
intravenous immunoglobulins, granulocyte or granulocyte macrophage colony stimulating 
factor, and oral glycerol.2 At present, none of the proposed adjunctive therapies are used in 
routine practice.
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Survivors of neonatal meningitis are at considerable risk for long-term neurologic 
impairment.68, 69 A prospective study that followed 1717 survivors of neonatal meningitis 
through 5 years of age found that those who had neonatal meningitis were 10 times more 
likely to have moderate or severe disability than children who never had meningitis.68 
Certain characteristics can help identify infected infants at the highest risk for a poor 
outcome (Box 5).70, 71
PREVENTING NEONATAL MENINGITIS
Intrapartum Antibiotic Prophylaxis
Since the adoption of IAP use in 1996 and universal antenatal screening for GBS 
colonization in 2002, the incidence of early-onset GBS infections has decreased 
significantly from 1.8 cases per 1000 live births in 1990 to 0.26 cases per 1000 live births in 
2010.72 The incidence of late-onset GBS disease remains unaffected by IAP use.30, 72
IAP use has also been implicated in the increased proportion of non-GBS early-onset 
infections seen in VLBW infants. Since the late 1990s, E. coli has surpassed GBS as the 
predominant pathogen observed in early-onset infections among VLBW infants.6, 21–23 This 
likely reflects the success of IAP in reducing the incidence of early-onset GBS infections 
rather than an increase in the incidence of non-GBS infections.73 This change in proportion 
of non-GBS early-onset infections has not been observed in term infants.6
Reports from single-center studies have associated frequent use of ampicillin for IAP with 
an increase in ampicillin-resistant E. coli infections, particularly in premature infants.22, 74 
However, rates of ampicillin-resistant E. coli have also increased in the general 
community.20 Furthermore, a multicenter trial involving 389 infants with confirmed early-
onset sepsis found that, when comparing infants exposed and not exposed to IAP, 
frequencies of ampicillin-resistant E. coli infections were not significantly different.6 
Although GBS has become increasingly resistant to clindamycin and erythromycin, 
sensitivity to ampicillin remains unchanged.75.
GBS Vaccine
Vaccines against GBS can reduce the number of missed opportunities for screening and IAP 
administration due to false-negative screens, precipitous deliveries, or extremely preterm 
births.6, 72 Maternal immunity to the most common serotypes of GBS can be transferred 
passively to the infant and protect against early- and late-onset infections.76 A trivalent GBS 
vaccine has shown promise in phase I and II trials, with another phase II trial currently 
recruiting participants (Table 5).76
SUMMARY
Neonatal meningitis is a devastating disease that requires a high index of suspicion, prompt 
diagnosis, and rapid treatment. While the incidence and mortality have declined with 
improved neonatal intensive care practices and universal adoption of preventative screening 
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and prophylaxis programs, the associated morbidity remains unchanged. Performing an LP 
to collect CSF is critical to confirming the diagnosis, determining the causative pathogen, 
and refining antimicrobial therapy. Through better diagnostic practices and development of 
vaccines, there is great hope that we may further reduce the burden of this devastating 
disease.
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Mechanisms for Development of Neonatal Meningitis
1 Primary bloodstream infection with secondary hematogenous spread to CNS
2 Presence of an infectious foci with secondary bloodstream infection and hematogenous spread 
(e.g., osteomyelitis)
3 Presence of an infectious foci with direct extension into the CNS (e.g., sinus infection)
4 Primary CNS infection resulting from disruptions due to head trauma, neurosurgery, or congenital 
defects (e.g., myelomeningocele)
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Bacterial Mechanisms for Entry into the Cerebrospinal Fluid
1 Transcellular movement across the endothelial cell (e.g., GBS, Escherichia coli)
2 Paracellular movement by disruption of intercellular tight junctions
3 Transport across the blood-brain barrier and blood-CSF barriers within phagocytes (e.g., Listeria 
monocytogenes)
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Risk Factors for Neonatal Meningitis
1 Prematurity
2 Maternal rectovaginal GBS colonization
3 Chorioamnionitis or maternal fever
4 Premature rupture of membranes
5 Prolonged rupture of membranes >18 hours
6 Invasive fetal monitoring
7 Very low birth weight (<1500 g)
8 Prolonged hospitalization
9 Presence of external devices (e.g., reservoirs, shunts, catheters)
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Clinical Signs of Neonatal Meningitis
1 Fever or hypothermia
2 Irritability or lethargy
3 Hypotonia







11 Bulging anterior fontanel
12 Nuchal rigidity
13 Jaundice
14 Hypo- or hyperglycemia
15 Diarrhea
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Predictors of Poor Neurologic Outcomes in Survivors of Bacterial 
Meningitis
1 Seizures lasting >72 hours
2 Presence of coma
3 Hypotension requiring inotropic support
4 White blood cell count ≤5000 x 109/L
5 Abnormal electroencephalogram findings
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• Neonatal bacterial meningitis is uncommon but associated with high mortality 
and morbidity.
• Group B Streptococcus (GBS) is the most common cause of neonatal 
meningitis.
• Escherichia coli has recently become the most common pathogen isolated from 
very-low-birth-weight infants with meningitis.
• Infants with culture-proven meningitis can have negative blood cultures and 
normal cerebrospinal fluid parameters.
• All infants exhibiting signs of infection and with suspected early- or late-onset 
sepsis should undergo a lumbar puncture.
• A GBS vaccine for the prevention of neonatal GBS disease including meningitis 
is currently under development.
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What is the current practice?
Neonatal Bacterial Meningitis
Best Practice/Guideline/Care Path Objective(s)
• Promptly diagnose with performance of lumbar puncture
• Begin antibiotics without delay
• Reduce mortality and prevent long-term neurodevelopmental impairment
What changes in current practice are likely to improve outcomes?
• Collection of CSF in all stable, symptomatic infants suspected of early- or late-
onset infections with additional signs beyond respiratory distress
• Increased vigilance in identifying and treating mothers with GBS colonization
• Introduction of an effective GBS vaccine in the prevention of neonatal GBS 
disease
Is there a clinical algorithm?
Major Recommendations
• Perform a lumbar puncture on all clinically stable infants with suspected sepsis 
and meningitis (Grade 1B)
• Begin empiric antibiotics in all cases of suspected sepsis and meningitis (Grade 
1A)
○ For suspected early-onset meningitis, consider ampicillin and 
gentamicin or cefotaxime in infants
○ For suspected late-onset meningitis, consider vancomycin in addition 
to ampicillin and gentamicin or cefotaxime
• Repeat the lumbar puncture in infants who fail to demonstrate clinical 
improvement 24–48 hours after initiation of antibiotics (Grade 1B)
• Repeat lumbar punctures are unnecessary in infants who demonstrate rapid 
clinical improvement after initiation of antibiotics and at end of successful 
therapy (Grade 1B)
• All infants with a history of bacterial meningitis should be followed long-term 
for development of neurological sequelae (Grade 1A)
Bibliographic Source(s)
Heath, P.T., I.O. Okike, and C. Oeser, Neonatal meningitis: can we do better? Adv Exp 
Med Biol. 2011;719:11–24.
Heath, P.T. and I.O. Okike, Neonatal bacterial meningitis: an update. Paediatr Child 
Health. 2010;20:526–530.
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Verani, J.R., L. McGee, and S.J. Schrag, Prevention of perinatal group B streptococcal 
disease--revised guidelines from CDC, 2010. MMWR Recomm Rep. 2010;59(Rr-10):1–
36.
Summary statement
A high-index of suspicion, prompt diagnosis, and rapid initiation of antibiotics are 
essential to reducing mortality and morbidity associated with neonatal bacterial 
meningitis.
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Incidence of neonatal meningitis across the world. Data from references 2, 11–15.
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Table 1
Common pathogens of meningitis and commonly used empiric antibiotics
Type Major Pathogens Empiric Antibiotics
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Table 3
Available studies on biomarkers for neonatal meningitis
Biomarker N (ref) Study Population Notable Findings
Complete blood count differential ratio
72 (53) Term
<4 weeks PNA
Complete blood count differential 
ratio <1.5 as cutoff for predicting 




  positive predictive value=47%
  negative predictive value=100%
40 (54) Term
<28 days PNA
Used same cutoff values as above 




  positive predictive value=39%
  negative predictive value=81%
Peripheral white blood cell count 8312 (44) ≥34 weeks GA
0–150 days PNA
Use as predictor for bacterial 
meningitis had positive likelihood 
ratio <1.0
Neither sensitive nor specific
C-reactive protein, cerebrospinal fluid 23 (55) 28–41 weeks GA
0–6 weeks PNA
1/7 infants without infection, 0/5 
infants with sepsis without 
meningitis, and 2/11 infants with 
meningitis had C-reactive protein 
>1 mg/dl
Levels do not distinguish between 
infants with meningitis from those 
with no confirmed infection
GA, gestational age; PNA, postnatal age. 
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Table 4
Common antibiotics used to treat neonatal meningitis
Antibiotic (ref) Susceptible Bacteria Notes
Penicillin G (61) GBS Monotherapy acceptable if GBS confirmed by culture and clinical 
improvement is observed
Ampicillin (2, 6, 62, 63) GBS
L. monocytogenes Enterococcus sp.
17–78% of E. coli isolates resistant
Poor CNS penetration
Requires higher doses for meningitis






Synergistic effect with ampicillin in treatment of L. monocytogenes
Pseudomonas sp. may require combination therapy with a second agent
Requires therapeutic drug monitoring





Used instead of gentamicin in cases of suspected or confirmed meningitis
Not active against L. monocytogenes or Enterococcus sp.






Limit use to multidrug resistant organisms (e.g., extended-spectrum beta-
lactamase-producing organisms)
Vancomycin (62, 66) Coagulase-negative staphylococci
S. aureus Enterococcus sp.
Variable CNS penetration
Effective against methicillin-resistant S. aureus
Requires therapeutic drug monitoring
Nafcillin (66, 67) Methicillin-sensitive S. aureus Good CNS penetration
Superior to vancomycin for treatment of methicillin-sensitive S. aureus
GA, gestational age (weeks); PNA, postnatal age (days); SCr, serum creatinine (mg/dL).
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